{"filings":[{"id":611841,"accession_number":"0001140361-26-022633","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2026-05-22T21:15:41+00:00","items":["1.01","9.01"],"status":"ready","headline":"Anteris Technologies enters $250M ATM equity offering with TD Cowen to fund DurAVR heart valve development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into Sales Agreement with TD Securities (USA) LLC for at-the-market offering of up to $250M of common stock.","Commission payable to TD Cowen is 3.0% of gross proceeds for sales as agent.","Net proceeds primarily for ongoing development of DurAVR Transcatheter Heart Valve System and working capital.","Sales may be made on Nasdaq, in negotiated transactions, or block trades; company controls timing and size.","Offering terminates upon sale of all shares or either party giving 10 days' notice; shelf effective since Jan 8, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":49490,"accession_number":"0001140361-26-020901","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2026-05-13T00:55:30+00:00","items":["5.02"],"status":"ready","headline":"Anteris appoints Susan Knight and Stephen Denaro to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ms. Knight appointed as Class I Director with term expiring at 2028 annual meeting; joins Audit & Risk Committee.","Ms. Knight most recently Board Chair of Surmodics; former SVP & CFO of MTS Systems and VP Finance at Honeywell.","Mr. Denaro appointed as Class II Director with term expiring at 2026 annual meeting; also serves as Company Secretary for Australian subsidiaries (annual fee AUD 57,645).","Ms. Knight receives initial RSU grant of $250,000 vesting over three years; Mr. Denaro eligible for $125,000 annual RSU grant.","Company entered indemnification agreements with both new directors effective May 11, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":49491,"accession_number":"0001140361-26-020896","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2026-05-13T00:39:53+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anteris raises $320M, Q1 cash burn $28.7M; PARADIGM trial enrols in US","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net operating cash outflows of $28.7M for Q1 2026, funding PARADIGM Trial and manufacturing scale-up.","R&D expenses $17.5M, driven by clinical trial costs, manufacturing process validation, and headcount expansion.","Completed $320M capital raises in January 2026 to support PARADIGM Trial and global commercialization of DurAVR THV.","Post quarter-end, US patient enrollment in the PARADIGM Trial commenced; CMS coverage determination supports reimbursement.","Presented EMBARK Study and EFS data at CRT 2026 and Sydney Valves 2026."],"consensus_eps_estimate":-0.1566,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":494000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97187,"accession_number":"0001140361-26-017846","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Anteris terminates v2v development deal, pays $400K break fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Notified v2vmedtech of discontinuation of development contributions after Stage 1 completion.","Break fee of $400,000 payable to v2v; no further contribution obligations.","v2v shareholders may either buy back Anteris' equity at cost or reduce it to capped minority.","Related Development Agreement will terminate upon break fee payment.","Company expects no material adverse effect on consolidated financial position."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97186,"accession_number":"0001140361-26-016435","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Anteris Technologies signs 11-year lease for 181,436 sq ft in Brooklyn Park, MN","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease executed April 23, 2026; initial term from Sept 1, 2026 to Aug 31, 2037.","Monthly base rent starts at $152,708.63 with annual escalations and additional taxes/operating costs.","Full rent abatement for first 3 months; partial abatement for following 9 months if not in default.","Two extension options of 84 months (7 years) each at market rent.","Subsidiary Anteris Technologies Corporation leases office/warehouse space via Northcross West Industrial Owner, LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111756,"accession_number":"0001140361-26-007568","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Anteris Technologies grants CFO Matthew McDonnell $500K in RSUs vesting over three years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Compensation Committee approved RSU grant to CFO Matthew McDonnell valued at $500,000, effective March 4, 2026.","Number of RSUs determined by dividing $500,000 by closing stock price on grant date.","One-third vests on each of first three anniversaries; full acceleration on death, disability, or qualifying change-in-control termination.","Described as one-time special award for exemplary service, not affecting 2026 annual equity target."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111755,"accession_number":"0001140361-26-007003","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anteris reports FY2025 revenue down 29%, net loss widens to $94M; starts PARADIGM trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $1.9M (-29% YoY); net loss $94.1M (23% wider); cash used in ops $77.8M.","R&D expenses $69.1M focused on DurAVR THV trial preparation; SG&A $26.1M.","Initiated global PARADIGM pivotal trial for DurAVR THV; FDA IDE approval in Q4 2025.","Raised $320M in early 2026 including Medtronic investment to fund trial and commercialization.","Net tangible assets per share turned negative to ($0.01) from $1.74; all IPO proceeds fully used."],"consensus_eps_estimate":-0.5959,"consensus_eps_actual":-2.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":1913000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111754,"accession_number":"0001140361-26-002070","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Medtronic makes $90M strategic investment in Anteris; combined $320M capital raise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Medtronic invested $90M in Anteris via stock purchase; Anteris also completed an underwritten common stock offering for total gross proceeds of $320M.","Proceeds to fund global pivotal PARADIGM trial and global commercialization of DurAVR THV (transcatheter heart valve).","PARADIGM trial is a randomized controlled trial of ~1000 patients comparing DurAVR THV to commercially available TAVRs; enrollment started Q4 2025.","Medtronic and Anteris may expand collaboration into other strategic areas; Medtronic joins Anteris' stockholder community."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111753,"accession_number":"0001140361-26-001938","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Anteris raises ~$320M via public offering and Medtronic PIPE for DurAVR THV trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 40M shares at $5.75 (including full over-allotment); gross proceeds ~$230M.","Medtronic subsidiary invests $90M via PIPE at same $5.75 price; gets board observer and participation rights.","Proceeds to fund PARADIGM pivotal trial of DurAVR THV, expand manufacturing, and v2vmedtech R&D.","Offering and PIPE expected to close Jan 22, 2026; officers/directors subject to 90-day lock-up.","Medtronic's shares subject to transfer restrictions until May 2027 and volume limits through Jan 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128387,"accession_number":"0001140361-25-045444","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Stephen Denaro resigns from Anteris Technologies Board effective Dec 13, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Denaro resigned from the Board of Directors as a Class II director, effective December 13, 2025.","Resignation was not due to any disagreement with the Company or its management.","Denaro continues as corporate secretary of Anteris Technologies Pty Ltd and director of Australian subsidiaries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128386,"accession_number":"0001140361-25-044257","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Anteris Technologies Global Corp. Reports Results of 2025 Annual Meeting of Stockholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected John Seaberg and Gregory Moss as Class I directors with 14,305,918 and 15,653,027 votes for, respectively.","Ratified KPMG as independent auditor for 2025 with 20,620,868 votes for, 146,666 against, and 212,607 abstentions.","Approved grant of 1,000,000 RSUs to Wayne Paterson and other RSU grants to Seaberg, Denaro, Moss, and Roberts connected to the IPO and annual meeting.","Approved adjustments to exercise price of stock options under the Employee Incentive Plan and amendments to the 2017 and 2020 Incentive Plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128385,"accession_number":"0001140361-25-043801","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Anteris Technologies not renewing supply agreement with 4C Medical for ADAPT tissue","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["On Nov 26, 2025, Anteris notified 4C Medical of non-renewal of Second Amended Supply and License Agreement.","Agreement supplied ADAPT tissue for 4C's transcatheter mitral/tricuspid valve devices; term would expire June 1, 2026.","No early termination penalties incurred; company states termination does not materially impact financial results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128384,"accession_number":"0001140361-25-042395","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anteris reports positive 30-day DurAVR THV outcomes in 100 small-annuli patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No valve-related mortality and no moderate/severe paravalvular leak at 30 days.","Mean gradient 8.2 mmHg; effective orifice area 2.2 cm², reflecting single-digit gradients.","97% freedom from moderate/severe prosthesis-patient mismatch vs 11-35% in SMART Trial.","Technical success rate 100% in the last 50 consecutive patient implants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128383,"accession_number":"0001140361-25-041723","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anteris reports Q3 2025 cash burn; FDA OK to start PARADIGM trial in US","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["FDA approved U.S. recruitment for PARADIGM Trial in Nov 2025; first patients treated in Denmark in Oct 2025.","Q3 2025: R&D expenses $16.8M, SG&A $5.8M; net operating cash outflow 9M $59.3M.","Cash and cash equivalents $9.1M as of Sep 30, 2025.","IPO net proceeds $80M used: $52.7M for DurAVR development, $18.3M for debt repayment and working capital.","Related party payments in Q3: $515k (director fees, CEO, CFO remuneration)."],"consensus_eps_estimate":-0.5808,"consensus_eps_actual":-1.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":1603000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128382,"accession_number":"0001140361-25-040087","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anteris obtains FDA approval to initiate PARADIGM pivotal trial for DurAVR THV","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved global IDE trial for DurAVR THV in severe aortic stenosis patients.","PARADIGM is a prospective RCT enrolling ~1,000 patients 1:1 across US, Europe, Canada.","Primary endpoint: all-cause mortality, all stroke, cardiovascular hospitalization at one year.","Trial co-chaired by Dr. Michael J. Reardon (Houston Methodist) and Prof. Stephan Windecker (Bern).","First patients already treated in Denmark; trial supports future PMA and parallel CE Mark approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128381,"accession_number":"0001140361-25-039514","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anteris enrolls & treats first patients in DurAVR THV global pivotal trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patients enrolled and successfully treated in PARADIGM Trial for DurAVR THV in severe calcific aortic stenosis.","Procedure performed by Prof. Dr. Ole De Backer at Rigshospitalet, Copenhagen University Hospital, Denmark.","Trial is a randomized controlled study (1:1 vs commercial TAVRs) enrolling ~1,000 patients in All Comers Cohort.","Primary endpoint: all-cause mortality, all stroke, cardiovascular hospitalization at one year post procedure.","Expands existing data set of 130 patients; plans to add sites across US, Europe, and Canada."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128380,"accession_number":"0001140361-25-039496","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Anteris Technologies closes $11.5M common stock and warrant offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 2,346,936 shares and 5-year warrants at $4.90/unit; gross proceeds ~$11.5M.","Additional 102,040 shares sold Oct 24 under same terms as initial offering.","CDI offering included 2,788,064 CDIs and warrants at A$7.50 per CDI.","Securities exempt from registration under Section 4(a)(2); resale registration to be filed.","Closing occurred Oct 27, 2025; proceeds use not specified in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128379,"accession_number":"0001140361-25-039290","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["3.02","7.01","9.01"],"status":"ready","headline":"Anteris Technologies raises ~$25M via unregistered placement of shares, CDIs, and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 2,244,896 shares at $4.90/share with 5-year warrants at $7.50; 2,788,064 CDIs at A$7.50 with warrants at A$11.50.","Offering expected to close Oct 27 (shares) and Oct 30, 2025 (CDIs); gross proceeds ~$25M.","Warrants exercisable six months after issuance; resale registration statement to be filed with SEC.","Exempt under Section 4(a)(2), Rule 506(b) for shares, Regulation S for CDIs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128378,"accession_number":"0001140361-25-038210","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Anteris sets first annual meeting for Dec 3, 2025; proposal deadline Oct 25","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting of Stockholders scheduled for December 3, 2025 (Dec 4 in Australia).","Record date for voting eligibility is October 30, 2025 (Oct 31 in Australia).","Stockholder proposals under Rule 14a-8 must be received by October 25, 2025 at 11:59 PM ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128377,"accession_number":"0001140361-25-038166","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anteris gets Danish clearance to start DurAVR THV global pivotal trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Danish Medicines Agency clears Anteris to initiate DurAVR THV PARADIGM Trial for severe calcific aortic stenosis.","Patient recruitment at Danish centers expected in 4Q 2025; trial to enroll ~1000 patients, 1:1 vs. commercial TAVR.","IDE under FDA review; U.S. approval expected soon to allow U.S. sites in the trial.","Study co-chairs Dr. Michael Reardon and Prof. Stephan Windecker; CMO Chris Meduri cites potential to transform care.","Company calls approval a watershed moment, beginning commercialization planning for PMA and CE Mark."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145186,"accession_number":"0001140361-25-036430","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Anteris delays PARADIGM pivotal trial enrollment to Q4 2025 after FDA request","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patient enrollment in PARADIGM trial now expected Q4 2025, previously Q3 2025.","FDA requested additional bench testing info; company submitted formal response to IDE.","Regulatory submissions to European authorities are underway for multi-regional trial.","Stockholders approved ASX waiver proposal (13.66M for, 2.60M against) at Sept 29 special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145185,"accession_number":"0001140361-25-035449","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anteris Technologies adjourns special meeting to Sept 29 due to insufficient quorum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting of Sept 18, 2025 adjourned without business due to lack of required quorum.","Adjourned meeting rescheduled for Sept 29, 2025 at 8:00 a.m. CT; record date remains Aug 11, 2025.","Proposals include ASX waiver for new securities issuance under Listing Rule 7.1 and adjournment approval.","Board unanimously recommends voting FOR proposals; voting deadlines: Internet/phone by Sept 28, mail by Sept 26.","Holders who already voted need not take action; CDI holders have additional instructions and earlier deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145184,"accession_number":"0001140361-25-034636","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Anteris postpones special stockholder meeting to Sept 18 for broader participation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting postponed from Sept 11 to Sept 18, 2025; record date unchanged (Aug 11, 2025).","Board recommends voting FOR proposals in definitive proxy statement filed Aug 18, 2025.","Prior votes remain valid; new votes must be received by Sept 17 (proxies) or Sept 16 (CDI instructions).","Meeting will be held virtually via live webcast; details in press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145183,"accession_number":"0001140361-25-033879","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Anteris Technologies postpones Special Meeting to Sept 11 for broader stockholder voting","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Meeting postponed from Sept 4 to Sept 11, 2025; record date Aug 11 unchanged.","Company cites need for additional voting time to facilitate broader participation.","Board unanimously recommends voting FOR all proposals in the August 18 Proxy Statement.","Voting deadlines: proxies by Sept 10 (11:59 p.m. ET); CDI instructions by Sept 9 (5 p.m. CT)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145182,"accession_number":"0001140361-25-030297","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anteris Technologies reports Q2 2025 net loss $42.7M; cash $28.4M; 130 DurAVR implants","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from ordinary activities $1.17M for six months, down 16% YoY; net loss $42.7M, up 22% YoY.","130 patients implanted with DurAVR THV since start; 21 in Q2 2025; 79 clinical sites qualified for PARADIGM trial.","R&D expenses $16.3M in Q2 on PARADIGM trial preparation and manufacturing scale-up.","Cash and equivalents $28.4M at June 30, 2025; net operating cash outflow $41.0M in H1 2025.","No dividend declared; board appointed two new directors David Roberts and Gregory Moss."],"consensus_eps_estimate":-0.5387,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":1174000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145181,"accession_number":"0001140361-25-029341","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anteris Technologies gets ASX waiver from Listing Rule 7.1 on securities issuance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["ASX granted waiver from Listing Rule 7.1, allowing above-15% issuance without stockholder approval.","Waiver valid for three years from date of stockholder approval by special resolution (75% vote).","Company must remain compliant with Nasdaq listing rules and U.S. securities laws for issuances.","Waiver revocable if conditions fail, Nasdaq rules change, or ASX policy settings change.","Board says waiver provides flexibility for financing options consistent with U.S. public companies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145180,"accession_number":"0001140361-25-027864","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Anteris Technologies enters amended master services agreement with Switchback Medical","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Agreement covers development, manufacturing, engineering, and testing services at set prices per unit.","Company grants Switchback limited, exclusive, revocable license to certain IP solely for manufacturing.","Term expires March 31, 2028, with automatic one-year renewals unless terminated 180 days prior.","Company retains all rights to testing results, reports, data, and developed IP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163595,"accession_number":"0001140361-25-021859","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Anteris appoints Gregory Moss and David Roberts to board; Wenyi Gu resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gregory Moss appointed Class I Director, term expiring at 2025 annual meeting; serves on Nominating Committee.","David Roberts appointed Class III Director, term expiring at 2027 annual meeting; serves on Audit and Compensation Committees.","Each new director receives initial RSU grant of $250K vesting over 3 years, plus annual cash retainer, subject to ASX approval.","Dr. Wenyi Gu resigned effective June 5, 2025, with no disagreement with the company or management.","Indemnification agreements entered into with both Moss and Roberts per standard form."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163594,"accession_number":"0001140361-25-018725","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anteris Q1 net loss $21.9M (up 36%); sales $0.6M (-27%); DurAVR IDE submitted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.9M vs $16.2M a year ago; revenue $0.6M down 27% on lower tissue demand.","R&D spend $16.5M (+42%) driven by manufacturing scale-up ($3.5M) and PARADIGM trial prep ($1.5M).","Cash at March 31: $49.0M; IPO green-shoe raised $0.47M; included in Russell 2000.","DurAVR THV IDE for pivotal PARADIGM Trial submitted to FDA; 100+ patients treated; one-year data shows EOA 2.1 cm², MPG 8.6 mmHg, no valve mortality.","Manufacturing capacity scaled to 3x 2024 levels; ADAPT tissue sourced from US and Australia to mitigate supply risk."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":556000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181497,"accession_number":"0001140361-25-011072","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anteris reaches 100 patients treated with DurAVR THV; strong one-year safety and efficacy data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Over 100 patients treated with DurAVR THV, including de novo, valve-in-valve, and bicuspid cases.","65 patients completed 30-day primary endpoints; safety and efficacy demonstrated.","One-year data on 37 patients shows sustained large effective orifice areas and low mean pressure gradients.","No valve or cardiovascular mortality at one year; excellent safety profile.","Pivotal trial on track to commence Q3 2025, pending FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181496,"accession_number":"0001140361-25-009748","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anteris DurAVR THV reports zero PPM at one year in small annuli patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["One-year hemodynamic data: EOA 2.1±0.2 cm², mean gradient 8.6±2.6 mmHg, DVI 0.58 (n=65).","Zero prosthesis-patient mismatch (PPM) in small annuli patients; commercial valves report 11-35% PPM.","No valve or cardiovascular related mortality at one year; consistent safety profile.","Data to support planned IDE submission to FDA for DurAVR THV pivotal study.","Results presented at Sydney Valves late-breaking clinical trial session on March 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181495,"accession_number":"0001140361-25-008474","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anteris Technologies posts FY2024 net loss of $76M; auditor flags going concern doubt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss after tax $76.0M vs $46.8M in 2023; revenue flat at $2.7M.","Cash balance $70.5M at Dec 31, 2024, after US IPO net proceeds of ~$79.6M.","Net tangible asset backing per share $1.74 (Dec 2023: $1.04).","Auditor's report unmodified but includes Emphasis of Matter on going concern.","IDE submission for DurAVR THV pivotal trial on track for Q1 2025; 86 patients implanted to date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181494,"accession_number":"0001140361-25-007340","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Anteris Technologies appoints David St Denis as President and Class II director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective March 5, 2025; St Denis retains COO role and serves as CEO of v2vmedtech.","St Denis has been COO since July 2017; prior roles include Merck and Millennium Pharmaceuticals.","No material amendment to compensatory arrangements; no new grants or awards in connection.","St Denis will not sit on any Board committees due to non-independent status."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181493,"accession_number":"0001104659-25-003529","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anteris Technologies partial exercise of IPO over-allotment option for 78,481 shares at $6.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters partially exercised over-allotment option for 78,481 shares at $6.00 per share (less $0.42 discount).","Remaining over-allotment option lapsed on January 11, 2025.","Stabilisation manager TD Cowen ceased activities on Jan 12, 2025; purchased 2,141,519 shares during stabilisation at $5.14–$6.00.","IPO closed December 16, 2024; settlement of over-allotment occurred Jan 14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198285,"accession_number":"0001104659-24-130238","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["2.04"],"status":"ready","headline":"Anteris receives Obsidian redemption notice for convertible notes; owes ~$5.89M cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Obsidian required redemption of all convertible notes after IPO and reorganization close on Dec 16, 2024.","Company must pay $5,700,262.50 aggregate principal plus $191,010.00 in lieu of options by Dec 23, 2024.","Notes had a face value of $1.15 per note; 4,956,750 notes were issued on Nov 7, 2024.","Upon redemption, no notes outstanding under the facility; facility remains available for future drawdowns.","Payment uses cash on hand following the IPO of 14.8M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198284,"accession_number":"0001104659-24-128907","cik":2011514,"company_name":"Anteris Technologies Global Corp.","ticker":"AVR","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["3.02","3.03","5.03","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Anteris closes IPO raising $80M net; completes reorganization with ATL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 14.8M shares at $6.00/sh closed Dec 16, 2024; net proceeds $80.0M.","Reorganization via scheme of arrangement; ATL now wholly owned subsidiary.","Board divided into three classes: Class I (Seaberg), II (Denaro), III (Paterson, Gu).","Adopted Equity Incentive Plan and revised employment agreements with CEO, CFO, COO.","Charter amended to include classified board and 75% supermajority vote provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":874132933.7020317,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}